Clinical Trials Logo

Clinical Trial Summary

This prospective and open-label study evaluates the efficacy and safety of mFOLFIRINOX as postoperative chemotherapy in treating Chinese patients with pancreatic cancer after R0/R1 resection.


Clinical Trial Description

The patients will be treated with systemic FOLFIRINOX chemotherapy of adjusted dosage. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04224402
Study type Interventional
Source Sun Yat-sen University
Contact
Status Completed
Phase Phase 2
Start date January 31, 2020
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT06368063 - The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer Phase 4
Not yet recruiting NCT06375928 - EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial) N/A
Recruiting NCT06388967 - Pancreatic Cancer Detection Consortium
Completed NCT05483257 - Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma
Recruiting NCT05287165 - Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms Early Phase 1
Not yet recruiting NCT06287749 - French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
Recruiting NCT03977233 - Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer Phase 2
Recruiting NCT04736043 - Development of a Prediction Platform for Adjuvant Treatment and Prognosis in Resected Pancreatic Cancer Using Organoid
Terminated NCT03344172 - Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer Phase 2
Not yet recruiting NCT05479708 - ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
Not yet recruiting NCT05637567 - Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head Phase 2
Recruiting NCT05181605 - Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors Phase 2/Phase 3